Matches in SemOpenAlex for { <https://semopenalex.org/work/W750054087> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W750054087 abstract "OBJECTIVE: To characterize the spectrum of spinal movement disorders in NMO patients and examine symptomatic management trends. BACKGROUND: Spinal cord demyelination can cause several movement disorders in patients with neuromyelitis optica (NMO) and other demyelinating disorders. Although these abnormal movements could be the presenting symptom of the disease and at times the main source of disability, they are often overlooked, mislabeled, or undertreated. DESIGN/METHODS: We chart-reviewed 37 patients meeting diagnostic criteria for NMO or NMO spectrum disorder. We classified spinal movement disorders under 6 categories: tonic spasms (unclassified), extensor spasms, flexor spasms, focal dystonia, spinal myoclonus, and spinal-based tremors. We examined clinical and radiological data of symptomatic patients. RESULTS: We analyzed 37 patients (86.4[percnt] female mean age 51+/-17 years, mean disease duration 9.4+/-5.3 years). Twelve patients (32.4[percnt]) had paroxysmal tonic spasms, 2 (5.4[percnt]) had extensor spasms, 2 (5.4[percnt]) had flexor spasms, 2 (5.4[percnt]) had focal dystonia (cervical/arm), and 3 (8[percnt]) had postural/action tremors. No cases of spinal myoclonus idenitified. Pain was reported by 50[percnt] of patients with spasms. Patients with tonic spasms had lesions in their upper cervical/upper thoracic cord prior to or concomitant to spasm development. All patients with tremors and/or focal dystonia had lesions in the uppermost cervical cord and/or the cervicomedullary junction. There was no signal abnormality in the basal ganglia or the brainstem/cerebellum in any of the symptomatic patients. For management, antiepileptics were the most frequently used (gabapentin/pregabalin 14 patients, carbamezapine/oxycarbazipine 2), followed by muscle relaxants (baclofen 10, tizanidine 4), Baclofen pump (1), and botulinium toxin (1 patient with cervical dystonia). The abnormal movement was the main complaint at least at one post-hospitalization visit in all symptomatic patients. CONCLUSIONS: Movement disorders are common in NMO patients and can be a major source of disability. Randomized clinical trials are needed to identify effective treatments. Study Supported by: Disclosure: Dr. Abboud has nothing to disclose. Acorda Therapeutics; Sanofi; Viropharma, Inc.; NeuralStem, Inc.; Shire/Abvie; TerumoBCT" @default.
- W750054087 created "2016-06-24" @default.
- W750054087 creator A5027362230 @default.
- W750054087 creator A5086775272 @default.
- W750054087 date "2015-04-06" @default.
- W750054087 modified "2023-09-24" @default.
- W750054087 title "“Spinal” Movement Disorders in NMO Patients: An Under-Recognized Phenomenon (S46.001)" @default.
- W750054087 hasPublicationYear "2015" @default.
- W750054087 type Work @default.
- W750054087 sameAs 750054087 @default.
- W750054087 citedByCount "0" @default.
- W750054087 crossrefType "journal-article" @default.
- W750054087 hasAuthorship W750054087A5027362230 @default.
- W750054087 hasAuthorship W750054087A5086775272 @default.
- W750054087 hasConcept C118552586 @default.
- W750054087 hasConcept C126322002 @default.
- W750054087 hasConcept C187212893 @default.
- W750054087 hasConcept C2777641544 @default.
- W750054087 hasConcept C2778261627 @default.
- W750054087 hasConcept C2778559928 @default.
- W750054087 hasConcept C2779012798 @default.
- W750054087 hasConcept C2779134260 @default.
- W750054087 hasConcept C2779494072 @default.
- W750054087 hasConcept C2779761043 @default.
- W750054087 hasConcept C2780640218 @default.
- W750054087 hasConcept C2780775167 @default.
- W750054087 hasConcept C2781137167 @default.
- W750054087 hasConcept C42219234 @default.
- W750054087 hasConcept C71924100 @default.
- W750054087 hasConceptScore W750054087C118552586 @default.
- W750054087 hasConceptScore W750054087C126322002 @default.
- W750054087 hasConceptScore W750054087C187212893 @default.
- W750054087 hasConceptScore W750054087C2777641544 @default.
- W750054087 hasConceptScore W750054087C2778261627 @default.
- W750054087 hasConceptScore W750054087C2778559928 @default.
- W750054087 hasConceptScore W750054087C2779012798 @default.
- W750054087 hasConceptScore W750054087C2779134260 @default.
- W750054087 hasConceptScore W750054087C2779494072 @default.
- W750054087 hasConceptScore W750054087C2779761043 @default.
- W750054087 hasConceptScore W750054087C2780640218 @default.
- W750054087 hasConceptScore W750054087C2780775167 @default.
- W750054087 hasConceptScore W750054087C2781137167 @default.
- W750054087 hasConceptScore W750054087C42219234 @default.
- W750054087 hasConceptScore W750054087C71924100 @default.
- W750054087 hasLocation W7500540871 @default.
- W750054087 hasOpenAccess W750054087 @default.
- W750054087 hasPrimaryLocation W7500540871 @default.
- W750054087 hasRelatedWork W2038588513 @default.
- W750054087 hasRelatedWork W2080006832 @default.
- W750054087 hasRelatedWork W2089042498 @default.
- W750054087 hasRelatedWork W2118141454 @default.
- W750054087 hasRelatedWork W2124122074 @default.
- W750054087 hasRelatedWork W2162472632 @default.
- W750054087 hasRelatedWork W2163554652 @default.
- W750054087 hasRelatedWork W2197266161 @default.
- W750054087 hasRelatedWork W2330848534 @default.
- W750054087 hasRelatedWork W2398314964 @default.
- W750054087 hasRelatedWork W2412931075 @default.
- W750054087 hasRelatedWork W2533413385 @default.
- W750054087 hasRelatedWork W2584595536 @default.
- W750054087 hasRelatedWork W2999736780 @default.
- W750054087 hasRelatedWork W3010531606 @default.
- W750054087 hasRelatedWork W3015022271 @default.
- W750054087 hasRelatedWork W3039530339 @default.
- W750054087 hasRelatedWork W3148830144 @default.
- W750054087 hasRelatedWork W583358772 @default.
- W750054087 hasRelatedWork W2523678972 @default.
- W750054087 hasVolume "84" @default.
- W750054087 isParatext "false" @default.
- W750054087 isRetracted "false" @default.
- W750054087 magId "750054087" @default.
- W750054087 workType "article" @default.